Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer.SummaryDifference0.6%
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.9%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated to include new information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, along with a revision update from v2.16.1 to v2.16.2.SummaryDifference0.7%
- Check34 days agoChange DetectedThe page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, and it now features new references related to pembrolizumab and a randomized trial for non-small-cell lung cancer. Additionally, an older reference has been removed.SummaryDifference8%
- Check41 days agoChange DetectedThe web page has removed key references to clinical trials involving Pembrolizumab and its comparison with other treatment methods for non-small-cell lung cancer.SummaryDifference1%
- Check48 days agoChange DetectedThe page has added information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, referencing a specific study published in the New England Journal of Medicine.SummaryDifference0.6%
Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.